<Vitamin D receptor> expression is associated with <info type="GeneOrGeneProduct">PIK3CA</info> and <info type="GeneOrGeneProduct">KRAS</info> mutations in <info type="DiseaseOrPhenotypicFeature">colorectal cancer</info>.

<info type="ChemicalEntity">Vitamin D</info> is associated with decreased risks of various <info type="DiseaseOrPhenotypicFeature">cancers</info>, including <info type="DiseaseOrPhenotypicFeature">colon cancer</info>. The <info type="GeneOrGeneProduct">vitamin D receptor</info> (<info type="GeneOrGeneProduct">VDR</info>) is a transcription factor, which plays an important role in cellular differentiation and inhibition of proliferation. A link between <info type="GeneOrGeneProduct">VDR</info> and the <info type="GeneOrGeneProduct">RAS-mitogen-activated protein kinase</info> (<info type="GeneOrGeneProduct">MAPK</info>) or <info type="GeneOrGeneProduct">phosphatidylinositol 3-kinase</info> (<info type="GeneOrGeneProduct">PI3K</info>)-<info type="GeneOrGeneProduct">AKT</info> pathway has been suggested. However, the prognostic role of <info type="GeneOrGeneProduct">VDR</info> expression or its relationship with <info type="GeneOrGeneProduct">PIK3CA</info> or <info type="GeneOrGeneProduct">KRAS</info> mutation remains uncertain. Among 619 <info type="DiseaseOrPhenotypicFeature">colorectal cancers</info> in two prospective cohort studies, 233 (38%) tumors showed <info type="GeneOrGeneProduct">VDR</info> overexpression by immunohistochemistry. We analyzed for <info type="GeneOrGeneProduct">PIK3CA</info> and <info type="GeneOrGeneProduct">KRAS</info> mutations and <info type="GeneOrGeneProduct">LINE-1</info> methylation by Pyrosequencing, microsatellite instability (<info type="GeneOrGeneProduct">MSI</info>), and DNA methylation (<info type="GeneOrGeneProduct">epigenetic changes</info>) in eight CpG island methylator phenotype (<info type="GeneOrGeneProduct">CIMP</info>)-specific promoters [<info type="GeneOrGeneProduct">CACNA1G</info>, <info type="GeneOrGeneProduct">CDKN2A</info> (<info type="GeneOrGeneProduct">p16</info>), <info type="GeneOrGeneProduct">CRABP1</info>, <info type="GeneOrGeneProduct">IGF2</info>, <info type="GeneOrGeneProduct">MLH1</info>, <info type="GeneOrGeneProduct">NEUROG1</info>, <info type="GeneOrGeneProduct">RUNX3</info>, and <info type="GeneOrGeneProduct">SOCS1</info>] by <info type="GeneOrGeneProduct">MethyLight</info> (real-time PCR). <info type="GeneOrGeneProduct">VDR</info> overexpression was significantly associated with <info type="GeneOrGeneProduct">KRAS</info> mutation (odds ratio, 1.55; 95% confidence interval, 1.11-2.16) and <info type="GeneOrGeneProduct">PIK3CA</info> mutation (odds ratio, 2.17; 95% confidence interval, 1.36-3.47), both of which persisted in multivariate logistic regression analysis. <info type="GeneOrGeneProduct">VDR</info> was not independently associated with <info type="DiseaseOrPhenotypicFeature">body mass index</info>, <info type="DiseaseOrPhenotypicFeature">family history of colorectal cancer</info>, <info type="DiseaseOrPhenotypicFeature">tumor location</info> (<info type="DiseaseOrPhenotypicFeature">colon</info> versus <info type="DiseaseOrPhenotypicFeature">rectum</info>), <info type="DiseaseOrPhenotypicFeature">stage</info>, <info type="DiseaseOrPhenotypicFeature">tumor grade</info>, <info type="DiseaseOrPhenotypicFeature">signet ring cells</info>, <info type="GeneOrGeneProduct">CIMP</info>, <info type="GeneOrGeneProduct">MSI</info>, <info type="GeneOrGeneProduct">LINE-1 hypomethylation</info>, <info type="GeneOrGeneProduct">BRAF</info>, <info type="GeneOrGeneProduct">p53</info>, <info type="GeneOrGeneProduct">p21</info>, <info type="GeneOrGeneProduct">beta-catenin</info>, or <info type="GeneOrGeneProduct">cyclooxygenase-2</info>. <info type="GeneOrGeneProduct">VDR</info> expression was not significantly related with <info type="DiseaseOrPhenotypicFeature">patient survival</info>, <info type="DiseaseOrPhenotypicFeature">prognosis</info>, or <info type="DiseaseOrPhenotypicFeature">clinical outcome</info>. In conclusion, <info type="GeneOrGeneProduct">VDR</info> overexpression in <info type="DiseaseOrPhenotypicFeature">colorectal cancer</info> is independently associated with <info type="GeneOrGeneProduct">PIK3CA</info> and <info type="GeneOrGeneProduct">KRAS</info> mutations. Our data support potential interactions between the <info type="GeneOrGeneProduct">VDR</info>, <info type="GeneOrGeneProduct">RAS-MAPK</info> and <info type="GeneOrGeneProduct">PI3K-AKT</info> pathways, and possible influence by <info type="GeneOrGeneProduct">KRAS</info> or <info type="GeneOrGeneProduct">PIK3CA</info> mutation on <info type="DiseaseOrPhenotypicFeature">therapy</info> or <info type="DiseaseOrPhenotypicFeature">chemoprevention</info> targeting <info type="GeneOrGeneProduct">VDR</info>.